In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clicks: 239
ID: 272544
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.
Reference Key
x2020clinicalin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yao X;Ye F;Zhang M;Cui C;Huang B;Niu P;Liu X;Zhao L;Dong E;Song C;Zhan S;Lu R;Li H;Tan W;Liu D;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2020
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32150618
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE covid-19 sars-cov-2 animals pubmed abstract nih national institutes of health national library of medicine pandemics research support non-u.s. gov't cell line pneumonia viral / drug therapy* chlorocebus aethiops vero cells antiviral agents / pharmacology* lung / drug effects betacoronavirus / drug effects* coronavirus infections / drug therapy* pmid:32150618 pmc7108130 doi:10.1093/cid/ciaa237 xueting yao fei ye dongyang liu antiviral agents / pharmacokinetics chloroquine / pharmacokinetics chloroquine / pharmacology hydroxychloroquine / pharmacokinetics hydroxychloroquine / pharmacology* severe acute respiratory syndrome / drug therapy*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.